By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the past year there were no insider purchases at Regeneron Pharmaceuticals, Inc.. Seven insiders sold roughly $12.9 million instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
1,331 investment managers listed REGN in their latest 13F filings (Q2 2026); more funds sold than bought. Zooming out by quarter: 4 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. REGN also shows up in congressional disclosures: 20 reported trades from ten lawmakers in two years.
Are insiders buying or selling REGN stock?
In the last 12 months Regeneron Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $12.9 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in REGN?
The most recent open-market insider trade in REGN was filed on 2026-09-03.
How many institutions own REGN?
1,331 investment managers reported holding REGN in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded REGN?
Yes. Members of Congress reported 20 trades in REGN over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).